Back to Search
Start Over
Repurposing Drugs in Oncology (ReDO)—diclofenac as an anti-cancer agent
- Source :
- ecancermedicalscience
- Publication Year :
- 2016
- Publisher :
- Cancer Intelligence, 2016.
-
Abstract
- Diclofenac (DCF) is a well-known and widely used non-steroidal anti-inflammatory drug (NSAID), with a range of actions which are of interest in an oncological context. While there has long been an interest in the use of NSAIDs in chemoprevention, there is now emerging evidence that such drugs may have activity in a treatment setting. DCF, which is a potent inhibitor of COX-2 and prostaglandin E2 synthesis, displays a range of effects on the immune system, the angiogenic cascade, chemo- and radio-sensitivity and tumour metabolism. Both pre-clinical and clinical evidence of these effects, in multiple cancer types, is assessed and summarised and relevant mechanisms of action outlined. Based on this evidence the case is made for further clinical investigation of the anticancer effects of DCF, particularly in combination with other agents - with a range of possible multi-drug and multi-modality combinations outlined in the supplementary materials accompanying the main paper.
- Subjects :
- 0301 basic medicine
Oncology
Drug
Cancer Research
medicine.medical_specialty
media_common.quotation_subject
perioperative intervention
Context (language use)
Pharmacology
03 medical and health sciences
0302 clinical medicine
Diclofenac
Clinical investigation
Internal medicine
medicine
Repurposing
media_common
drug repurposing
business.industry
Cancer
Treatment Setting
ReDO project
medicine.disease
NSAID
diclofenac
Drug repositioning
030104 developmental biology
030220 oncology & carcinogenesis
Clinical Study
business
medicine.drug
Subjects
Details
- Language :
- English
- ISSN :
- 17546605
- Volume :
- 10
- Database :
- OpenAIRE
- Journal :
- ecancermedicalscience
- Accession number :
- edsair.doi.dedup.....d34122c6ff07ba32db65a44416ac2a03